Brandstetter R D, Gotz V P, Mar D D
Am J Hosp Pharm. 1980 Oct;37(10):1326-9.
The safety and efficacy of 0.1-, 0.3- and 0.5-mg doses of epinephrine hydrochloride in the initial treatment of an acute asthma attack were compared in a double-blind study. Epinephrine hydrochloride 1:1000 was injected subcutaneously in 45 emergency room patients suffering from an acute asthma attack. The patients randomly received 0.1, 0.3 or 0.5 mg of the drug. Arterial blood gases, pulmonary function, blood pressure and heart rate were measured before, and at 10 and 20 minutes after dosing. Bronchodilation, as measured by peak expiratory flow rate, occurred at all doses but was significantly greater (p < 0.05) with the 0.5-mg dose than with the 0.1-mg dose (at 10 and 20 minutes) and the 0.3-mg dose (at 20 minutes). Arterial blood gases, heart rate and blood pressure were not significantly different for the three groups (p > 0.05). The study suggests that a 0.5-mg subcantaneous dose represents optimal epinephrine dosing for the initial therapy of acute asthma.
在一项双盲研究中,比较了0.1毫克、0.3毫克和0.5毫克剂量的盐酸肾上腺素在急性哮喘发作初始治疗中的安全性和有效性。对45名患有急性哮喘发作的急诊室患者皮下注射1:1000的盐酸肾上腺素。患者随机接受0.1毫克、0.3毫克或0.5毫克的药物。在给药前、给药后10分钟和20分钟测量动脉血气、肺功能、血压和心率。以呼气峰值流速衡量的支气管扩张在所有剂量下均有发生,但0.5毫克剂量组在10分钟和20分钟时的支气管扩张程度显著大于(p<0.05)0.1毫克剂量组,在20分钟时显著大于0.3毫克剂量组。三组的动脉血气、心率和血压无显著差异(p>0.05)。该研究表明,0.5毫克皮下剂量是急性哮喘初始治疗的最佳肾上腺素给药剂量。